1	Frailty is associated with low physical activity and poor sleep quality in patients
2	undergoing myeloablative allogeneic hematopoietic cell transplantation:
3	A Fitbit® Pilot Study
4	
5	
6	Caryn R. Libbert ¹ , Fiona He ² , Najla El Jurdi ³ , Helen Fagrelius ⁴ , Mark Juckett ³ , Joseph
7	Maakaron ³ , William Juckett ⁵ , Nicholas Evanoff ⁵ , Donald R. Dengel ⁵ , Shernan G. Holtan ^{3,6}
8	
9	
10	¹ University of Minnesota Medical School, Minneapolis, MN
11	² Allina Health Cancer Institute, Minneapolis, MN
12 13	³ Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN
14	⁴ Clinical Trials Office, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
15	⁵ School of Kinesiology, University of Minnesota, Minneapolis, MN
16	⁶ Transplant and Cellular Therapies, Roswell Park Comprehensive Cancer Center, Buffalo, NY
17	

18 ABSTRACT

19

Allogeneic hematopoietic cell transplantation (alloHCT) is a vital therapy for various 20 hematologic diseases, though it demands high physiological resilience. Frailty, a syndrome 21 22 impacting the body's ability to withstand stress, affects outcomes of alloHCT across all ages. This study examines the relationship between frailty and peri-transplant activity and sleep 23 24 patterns using Fitbit® devices. In this pilot study, adults scheduled for their first myeloablative alloHCT at the University of Minnesota from June 2022 to January 2023 were included if they 25 had a compatible device for the Fitbit® app. Participants were monitored for activity and sleep 26 27 from admission to day +30 post-transplant. Frailty was assessed pre-transplant using Fried Phenotype criteria. Data were analyzed for activity and sleep patterns differences among not 28 frail, pre-frail, and frail groups. Nine patients provided sufficient data for analysis, showing 29 significant variances in activity levels and sleep patterns across frailty categories. Not frail 30 patients exhibited significantly higher daily steps and active minutes than pre-frail and frail 31 patients. Not frail patients also had the highest amount of restorative deep and rapid eve 32 movement sleep. Due to Fitbit methodology and likely frequent interruptions, 28% of the days in 33 the first month post-transplant had a recorded sleep time of 0 minutes. Although our sample size 34 35 was small, our findings underscore the importance of frailty in influencing activity and sleep patterns among alloHCT recipients. 36

37 INTRODUCTION

38

39 Allogeneic hematopoietic cell transplantation (alloHCT) is a critical treatment for various 40 hematologic conditions, replacing diseased marrow with healthy stem cells from a donor. Despite its effectiveness, alloHCT demands significant physiological resilience from patients. 41 42 Frailty, a syndrome characterized by a reduction in the body's physiologic reserve—the ability to 43 withstand stress and repair tissue damage—is not restricted to older individuals. It also affects younger patients undergoing alloHCT because of underlying disease or treatment-related 44 45 toxicities, leading to an increased risk of mortality and post-transplant complications (1-3). Frailty presents in physical, psychological, and social dimensions, affecting patients' ability to 46 cope with and recover from alloHCT. Recognizing the importance of monitoring patient well-47 being during treatment, this study employs Fitbit® devices to measure activityx and sleep 48 49 patterns—key health indicators during the peri-transplant period (4). While research has established the detrimental effects of frailty on alloHCT outcomes, the specific activity and sleep 50 51 patterns associated with varying degrees of frailty—not frail, pre-frail, and frail—remain 52 unexplored, particularly in myeloablative alloHCT settings among otherwise fit adults. Our pilot study aims to investigate these patterns, potentially guiding more personalized care to improve 53 54 quality of life and survival for alloHCT recipients.

55 **METHODS**

56 Patient Selection

We included adults (≥18 years) scheduled for their first myeloablative alloHCT at the University of Minnesota who had a smartphone or tablet compatible with the Fitbit® app from June 2022 to January 2023. Participants received a Fitbit® Sense device before their alloHCT hospitalization and were advised to stay active by walking within the hospital unit. Access to physical therapists and exercise facilities was provided. The study adhered to IRB approval and HIPAA guidelines, with all participants giving written informed consent.

63

64 Data Collection and Definitions

Participants synced their Fitbit® with a PHI-compliant Fitabase® at least weekly. We included data from admission until day +30 post-transplant, considering days with \geq 10 hours of wear time as evaluable days. Activity was measured via daily steps, active and sedentary time—active time being periods with \geq 3 METS energy expenditure. Sleep analysis included duration, deep sleep, and REM sleep. Frailty status, assessed pre-transplant using Fried Phenotype criteria (5), categorized individuals as frail (\geq 3 criteria), pre-frail (1-2 criteria), or not frail (no criteria), with data extracted from health records.

72

73 <u>Statistical Methods</u>

74 Descriptive statistics illustrated Fitbit® data by frailty status. Differences between not frail, pre-

frail, and frail groups were analyzed using Kruskal-Wallis tests and Dunn's multiple

76	comparisons for post hoc assessments. Smoothing spline regression curves show longitudinal
77	activity and sleep trends. Statistical analyses were completed using JMP Pro 17 (SAS
78	Corporation, Cary, NC) and GraphPad Prism version 9.4.1 (GraphPad Software, Boston, MA).
79	
80	RESULTS
81	Patient Characteristics
82	Nine patients with adequate data were included in the analysis. Median age was 48 (range 22 to
83	59); five patients were male and four were female. Two patients were categorized as frail, five as
84	pre-frail, and two as not frail prior to alloHCT. Additional patient characteristics are included in

85 Supplemental Table 1. The mean percentage of evaluable days between hospital admission to

day +30 was 81% \pm 22% with a mean wear time of 1307 \pm 198 minutes.

87

88 Patterns of Activity

Not frail patients had a higher mean of daily steps compared to pre-frail (2.4-fold higher, $8265 \pm$

90 5274 versus 3381 \pm 2757 steps, p < 0.0001) and frail (4.2-fold higher, 1977 \pm 1610 steps, p <

91 0.0001). Pre-frail patients had a higher mean of daily steps than frail (1.7-fold higher, p = 0.0103,

92 Figure 1a). Not frail patients also had a higher mean of active minutes compared to pre-frail (56

 ± 49 versus 20 ± 26 minutes, p < 0.0001) and frail (25 ± 47 minutes, p < 0.0001). There was no

significant difference in the mean of active minutes between pre-frail and frail patients

95 (p>0.9999). Not frail patients had a lower mean of sedentary minutes compared to both pre-frail

96 $(763 \pm 206 \text{ versus } 884 \pm 313 \text{ minutes}, p = 0.0064)$ and frail $(943 \pm 422 \text{ minutes}, p = 0.0004)$.

97 There was no statistically significant difference in the mean sedentary time between pre-frail and
98 frail patients (p=0.2472). Maximum sedentary time occurred around day +15 post-transplant
99 (Figure 1c).

100

101 Patterns of Sleep

Across all cohorts, there was a median percentage of 67% (range 0% to 100%) of evaluable days 102 103 including complete sleep data with sleep stages from admission to day +30. Overall, not frail 104 patients had the best sleep quantity and quality (Figure 1b). Not frail patients spent more time in REM sleep compared to pre-frail (52 ± 36 versus 33 ± 39 minutes, p = 0.0003) and frail (24 ± 43 105 106 minutes, p < 0.0001). Frail patients spent less time in deep sleep compared to pre-frail (11 ± 19) 107 versus 33 ± 34 minutes, p = 0.0003) and not frail (35 ± 24 minutes, p < 0.0001). There was a 108 median percentage of 28% (range 0% to 58%) of days with zero minutes of time asleep, a 109 median percentage of 36% (range 3% to 87%) of days with zero minutes of time in deep sleep, 110 and a median percentage of 36% (range 0% to 87%) of days with zero minutes of REM sleep as 111 measured by the Fitbit[®]. The sleep time nadir was also around day +15 post-transplant (Figure 112 1c).

113 **DISCUSSION**

Our study delineates the variances in activity and sleep patterns among three distinct frailty 114 115 phenotypes prior to transplantation. We discovered that patients without frailty exhibit higher daily step counts and more active time than their pre-frail and frail counterparts. Furthermore, 116 individuals classified as frail not only engaged in less physical activity but more surprisingly also 117 experienced diminished durations of restorative deep and REM sleep. The occurrence of days 118 119 without recorded sleep data suggests that sleep disruptions are prevalent across all patient 120 groups. Such disturbances may be partly explained by the Fitbit®'s methodology, which only logs sleep after an hour without movement and requires a three-hour minimum of sleep data to 121 122 analyze sleep stages (6, 7). The frequent nighttime awakenings, as reported by El Jurdi et al., 123 averaging 4.5 interruptions per night, are a probable factor in the poor sleep quality captured in our findings (4). 124

125

Previous research has linked frailty to decreased overall survival, increased non-relapse 126 mortality, and a decline in the quality of life (2, 3, 8, 9). The reduced activity and lack of 127 128 restorative sleep observed in frail patients are likely contributing to these negative health outcomes. Interventions tailored to the specific aspects of frailty in the elderly have been shown 129 130 to enhance physical condition, as noted by Cameron et al. (10). This insight opens the possibility 131 of applying similar targeted interventions to alloHCT patients, employing pre-transplant frailty assessments to inform and customize therapeutic strategies, potentially mitigating the impact of 132 133 frailty on post-transplant recovery and long-term well-being.

134

135 CONCLUSION


- 136 Our study demonstrated a reduced level of physical activity and poor sleep in individuals with
- 137 frailty undergoing myeloablative alloHCT. Recognizing these differences may allow for
- development of targeted interventions to reduce disease burdens of care and improve support
- 139 systems.

140 FIGURES

141

142 Figure 1: Patterns of (A) activity and (B) sleep based on phenotype of Frailty. The top of the bar 143 represents the mean with error bars representing standard deviation. Longitudinal sedentary time 144 and minutes asleep by transplant date are shown in C, with the line representing the smoothing 145 spline regression curves.

146



147

148 **REFERENCES**

- 149
- Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med.
 2011;27(1):1-15.
- Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic Frailty in
 Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow
- 154 Transplant Survivor Study. JAMA Oncol. 2016;2(10):1277-86.
- Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, et al.
 Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. Biol
 Blood Marrow Transplant. 2019;25(12):2454-60.
- El Jurdi N, Nock N, Fu P, Cao S, Cotton JM, Ali N, et al. Physical Activity and Sleep
 Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A
 Pilot Study. Transplant Cell Ther. 2021;27(6):502.e1-.e6.
- 5. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
- 164 6. How do I track my sleep with my Fitbit device? [Available from:
 165 https://help.fitbit.com/articles/en US/Help_article/1314.htm?Highlight=sleep%20.]
- 166 7. What should I know about Fitbit sleep stages? [Available from:
- 167 https://help.fitbit.com/articles/en_US/Help_article/2163.htm?Highlight=sleep%20.]
- Mohanraj L, Sargent L, Elswick RK, Toor A, Swift-Scanlan T. Factors Affecting Quality
 of Life in Patients Receiving Autologous Hematopoietic Stem Cell Transplantation.
 Cancer Nurs. 2022;45(2):E552-E9.
- Huan-Tze L, Yun-Ru L, Kuan-Der L, Huey-En T. Frailty in chronic myeloid leukemia:
 evidence from 2016–2018 Nationwide Inpatient Sample of the US. BMC Geriatrics.
 2023;23(1).
- 174 10. Cameron ID, Fairhall N, Langron C, Lockwood K, Monaghan N, Aggar C, et al. A
 175 multifactorial interdisciplinary intervention reduces frailty in older people: randomized
 176 trial. BMC Medicine. 2013;11(1):65.
- 177
- 178
- 179

